Wai-On Chu1,2, Pegdwende Olivia Dialla1,2, Patrick Roignot3, Marie-Christine Bone-Lepinoy4, Marie-Laure Poillot1,2, Charles Coutant5, Patrick Arveux1,2, Tienhan Sandrine Dabakuyo-Yonli6,7,8. 1. Breast and Gynaecologic Cancer Registry of Côte d'Or, Centre Georges François Leclerc Comprehensive Cancer Centre, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France. 2. EA 4184, Faculty of Medicine, University of Burgundy, Dijon, France. 3. Pathology Centre, 33 rue Nicolas Bornier, 21000, Dijon, France. 4. Centre Radiotherapie du Parc, 18 cours du General de Gaulle, 21000, Dijon Cedex, France. 5. Department of Surgical Oncology, Centre Georges François Leclerc Comprehensive Cancer Centre, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France. 6. EA 4184, Faculty of Medicine, University of Burgundy, Dijon, France. sdabakuyo@cgfl.fr. 7. Biostatistics and Quality of Life Unit, Centre Georges François Leclerc Comprehensive Cancer Centre, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France. sdabakuyo@cgfl.fr. 8. National Quality of Life and Cancer Clinical Research Platform, Dijon, France. sdabakuyo@cgfl.fr.
Abstract
PURPOSE: To identify the impact of clinical and socio-economic determinants on quality of life (QoL) among breast cancer (BC) survivors 5 years after diagnosis. METHODS: A cross-sectional survey was conducted in women diagnosed in 2007 for primary invasive non-metastatic BC and identified through the Côte d'Or BC registry. QoL was assessed with the Medical Outcomes Study 12-item Short Form Health Survey (SF-12), the European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30) and the breast cancer (EORTC-QLQ-BR23) questionnaires. Social support was assessed with Sarason's social support questionnaire, and deprivation was assessed by the EPICES questionnaire. Clinical variables were collected through the registry database. Determinants of QoL were identified using multivariable mixed model analysis for each SF-12 dimension. A sensitivity analysis was conducted with multiple imputations on missing data. RESULTS: Overall, 188 patients on 319 patients (59 %) invited to participate to the survey completed the questionnaires. Five years after breast cancer diagnosis, the disease stages at diagnosis, as well as the treatment received, were not determinants of QoL. Only the age at diagnosis and comorbidities were found to be determinants of QoL. CONCLUSIONS: Five years after BC diagnosis, disease severity and the treatment received did not affect QoL.
PURPOSE: To identify the impact of clinical and socio-economic determinants on quality of life (QoL) among breast cancer (BC) survivors 5 years after diagnosis. METHODS: A cross-sectional survey was conducted in women diagnosed in 2007 for primary invasive non-metastatic BC and identified through the Côte d'Or BC registry. QoL was assessed with the Medical Outcomes Study 12-item Short Form Health Survey (SF-12), the European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30) and the breast cancer (EORTC-QLQ-BR23) questionnaires. Social support was assessed with Sarason's social support questionnaire, and deprivation was assessed by the EPICES questionnaire. Clinical variables were collected through the registry database. Determinants of QoL were identified using multivariable mixed model analysis for each SF-12 dimension. A sensitivity analysis was conducted with multiple imputations on missing data. RESULTS: Overall, 188 patients on 319 patients (59 %) invited to participate to the survey completed the questionnaires. Five years after breast cancer diagnosis, the disease stages at diagnosis, as well as the treatment received, were not determinants of QoL. Only the age at diagnosis and comorbidities were found to be determinants of QoL. CONCLUSIONS: Five years after BC diagnosis, disease severity and the treatment received did not affect QoL.
Entities:
Keywords:
Breast cancer; Determinant of quality of life; Long-term survivor; Social support; Socio-economics factors
Authors: Martin Fortin; Gina Bravo; Catherine Hudon; Lise Lapointe; José Almirall; Marie-France Dubois; Alain Vanasse Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Candyce H Kroenke; Marilyn L Kwan; Alfred I Neugut; Isaac J Ergas; Jaime D Wright; Bette J Caan; Dawn Hershman; Lawrence H Kushi Journal: Breast Cancer Res Treat Date: 2013-05-09 Impact factor: 4.872
Authors: B Gandek; J E Ware; N K Aaronson; G Apolone; J B Bjorner; J E Brazier; M Bullinger; S Kaasa; A Leplege; L Prieto; M Sullivan Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: A Belot; P Grosclaude; N Bossard; E Jougla; E Benhamou; P Delafosse; A-V Guizard; F Molinié; A Danzon; S Bara; A-M Bouvier; B Trétarre; F Binder-Foucard; M Colonna; L Daubisse; G Hédelin; G Launoy; N Le Stang; M Maynadié; A Monnereau; X Troussard; J Faivre; A Collignon; I Janoray; P Arveux; A Buemi; N Raverdy; C Schvartz; M Bovet; L Chérié-Challine; J Estève; L Remontet; M Velten Journal: Rev Epidemiol Sante Publique Date: 2008-06-10 Impact factor: 1.019
Authors: Adam W Glaser; Lorna K Fraser; Jessica Corner; Richard Feltbower; Eva J A Morris; Greg Hartwell; Mike Richards; Richard Wagland Journal: BMJ Open Date: 2013-04-10 Impact factor: 2.692
Authors: Maria Antonietta Annunziata; Barbara Muzzatti; Cristiana Flaiban; Katiuscia Gipponi; Carlo Carnaghi; Paolo Tralongo; Michele Caruso; Raffaele Cavina; Umberto Tirelli Journal: Support Care Cancer Date: 2017-09-16 Impact factor: 3.603
Authors: Mirelle Lagendijk; Elizabeth Mittendorf; Tari A King; Christopher Gibbons; Andrea Pusic; Laura S Dominici Journal: Oncologist Date: 2019-12-17
Authors: Ana Isabel Cobo-Cuenca; Noelia María Martín-Espinosa; María Aurora Rodríguez-Borrego; Juan Manuel Carmona-Torres Journal: Qual Life Res Date: 2018-10-15 Impact factor: 4.147